KNSA — KINIKSA PHARMACEUTICALS INTL

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About KINIKSA PHARMACEUTICALS INTL (KNSA)

KINIKSA PHARMACEUTICALS INTL (KNSA) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $34M. All data sourced from SEC 13F filings.

Tracked investors reporting KNSA

  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    564.4K
    Value
    $27.2M
    % Portfolio
    0.01%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    641K
    Value
    $30.9M
    % Portfolio
    0.04%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    499.7K
    Value
    $24.1M
    % Portfolio
    0.00%

Recent activity

  • No recent activity.

Frequently asked questions

How many institutional investors hold KNSA?
3 tracked institutional investors disclosed a position in KNSA (KINIKSA PHARMACEUTICALS INTL) in their most recent 13F filing.
Who is the largest institutional holder of KNSA?
Izzy Englander, Millennium Management, holds the largest disclosed position in KNSA, valued at $34M.
Did institutional ownership of KNSA increase or decrease?
Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited KNSA.
Where does this KNSA ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
KNSA (KINIKSA PHARMACEUTICALS INTL) — Institutional Holders — InvestorLens